CABOLONG 40 MG

Treatment decisions involving Cabozantinib are closely tied to the disease settings recorded here: Renal cell carcinoma; hepatocellular carcinoma after sorafenib; differentiated thyroid cancer in selected settings. Inhibits multiple receptor tyrosine kinases including VEGFR, MET and AXL. Its activity across vascular and other kinase pathways gives it a broader molecular footprint than a single-target inhibitor, helping explain its use across several tumor types. It is categorized as Targeted Therapy; Multikinase Inhibitor, with Renal Cell Carcinoma; Hepatocellular Carcinoma; Thyroid Cancer listed as the principal tumor types. The regimen field includes Cabozantinib monotherapy; nivolumab + cabozantinib. Those combinations are clinically meaningful because the same medicine can have a different role when paired with endocrine therapy, chemotherapy, another targeted agent, or supportive treatment. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. For clinicians reviewing the database, the drug name should therefore be interpreted together with histology, stage, prior therapy, and the relevant biomarker or eligibility requirement. Its pharmacologic class provides useful context, but does not replace disease-specific selection criteria. The wording is intended as a reference synthesis rather than a prescribing protocol and deliberately avoids individualized dose recommendations. Oncology approvals and guideline-supported uses can change over time, so contemporary labeling remains important.